Fig. 7

Targeting ESRRG enhances the efficacy of anti–PD-1 therapy. A MCPcounter algorithm employed to examine the correlations between ESRRG expression and immune infiltration cells. B TIDE scores were lower in the ESRRG high-expression group. C Schematic diagram of administration cycles in mice. Tumor growth D, E and tumor burdens (F) of AKR xenografts treated with control (vehicle) or DY131 combined with IgG2a or anti–PD-1 mAb (n = 5). G, H Quantification of tumor-infiltrating immune cells, GZMB⁺ CD8⁺ cells and IFN-γ⁺ CD8⁺ cells analyzed by flow cytometry using the indicated cell surface markers and in control and DY131 group. *P < 0.05 or **P < 0.01 indicates significant differences from the vehicle group as assessed by a one-way ANOVA with a post hoc Dunnett’s test